Table 1 Urinary concentrations (nmol mmol−1 creatinine)

From: Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples

  

n

Mean

s.d.

Min

Max

25th p

Median

75th p

HP

Group 1a

12

136.70

52.86

56.00

212.50

90.18

145.50

181.05

 

Group 1b

12

64.62

34.08

13.80

128.20

39.98

58.90

85.25

 

Group 2a

8

76.81

41.58

23.10

141.30

37.75

75.05

106.50

 

Group 2b

8

37.59

18.65

16.60

70.83

21.03

32.05

51.38

 

Group 3a

8

117.02

58.35

49.21

222.50

69.63

97.06

161.62

 

Group 3b

8

134.26

47.66

71.06

193.94

98.82

118.94

186.30

 

Group 4

74

50.34

20.47

13.20

94.10

36.02

48.85

66.00

LP

Group 1a

12

30.86

7.30

21.02

40.43

23.50

31.92

38.02

 

Group 1b

12

12.84

6.49

4.72

22.80

8.00

9.82

18.90

 

Group 2a

8

11.93

5.61

5.50

19.73

5.90

12.67

17.56

 

Group 2b

8

8.53

3.85

2.97

13.83

5.48

8.02

12.22

 

Group 3a

8

23.95

5.60

14.37

34.13

21.30

23.84

26.41

 

Group 3b

8

31.42

7.65

23.27

48.43

26.91

29.36

33.43

 

Group 4

74

9.32

4.43

1.80

19.10

5.67

8.85

12.58

  1. Group 1a=OSCC with mandibular bony infiltration; group 1b=patients in group 1a >6 months after successful treatment; group 2a=OSCC without mandibular bony infiltration; group 2b=patients in group 2a >6 month after successful treatment; group 3a=untreatable recurrence of OSCC; group 3b=patients in group 3a at least 6 weeks later, symptoms unchanged and group 4=control group, patients without disease n=74. s.d.=standard deviation, min=minimum, max=maximum, p=percentile.